Article Sidebar

Download
PDF

Main Article Content

Abstract

Formulation of poorly water-soluble drugs for oral drug delivery has always been a difficult task for formulation scientists. Lurasidone hydrochloride is one such agent which is used to control bipolar depression. The objective of this study was to formulate and optimize lurasidone nanosuspension, further formulating optimized nanosuspensions as fast disintegrating tablets for improved patient compliance. In the present study, lurasidone nanosuspension was prepared by nanomilling technique. Optimized nanosuspension has mean particle diameter of 248.9 nm, polydispersity index of 0.127 and zeta potential of 18.1 mV. The lyophilized optimized nanocrystals, optimize nanosuspension as granulating fluid and as top spraying dispersion for granulation in fluid bed granulator being used to formulate fast disintegrating tablets with suitable super disintegrant. Croscarmellose sodium was found to be best superdisintegrant compared to sodium starch glycolate and crospovidone, as its acts by both mechanism swelling and wicking. Its swells 4-8 folds in less than 10 s. Many folds increase in the rate of drug release observed compare to micronized lurasidone and marketed product. There was no change in crystalline nature after nanomilling as characterized by XRD and FTIR, and it was found to be chemically stable with high drug content. The developed fast disintegrating tablets would be an alternative better formulation than its conventional formulation to address its bioavailability issue and for improved patient compliance. However, this should be further confirmed by appropriate in vivo studies.

Keywords

Nanosuspension Lurasidone Nanomilling Fast disintegrating Tablets Optimization

Article Details

How to Cite
Sankar Sahoo, S., & Babu Rao, C. (2019). Design, Optimization and Evaluation of Lurasidone Hydrochloride Nanocrystals as Fast Disintegrating Tablets. Asian Journal of Organic & Medicinal Chemistry, 4(2), 121–129. https://doi.org/10.14233/ajomc.2019.AJOMC-P209
Download Citation
Endnote/Zotero/Mendeley (RIS)
BibTeX

References

  1. S.V. Sastry, J.R. Nyshadham and J.A. Fix, Recent Technological Advances in Oral Drug Delivery-A Review, Pharm. Sci. Technol. Today, 3, 138 (2000); https://doi.org/10.1016/S1461-5347(00)00247-9.
  2. W.-M. Bahk, Y.S. Woo and H.R. Wang, Lurasidone as a Potential Therapy for Bipolar Disorder, Neuropsychiatr. Dis. Treat., 9, 1521 (2013); https://doi.org/10.2147/NDT.S51910.
  3. T. Ishibashi, T. Horisawa, K. Tokuda, T. Ishiyama, M. Ogasa, R. Tagashira, K. Matsumoto, H. Nishikawa, Y. Ueda, S. Toma, H. Oki, N. Tanno, I. Saji, A. Ito, Y. Ohno and M. Nakamura, Pharmacological Profile of Lurasidone, A Novel Antipsychotic Agent with Potent 5-Hydroxy-tryptamine 7 (5-HT7) and 5-HT1A Receptor Activity, J. Pharmacol. Exp. Ther., 334, 171 (2010); https://doi.org/10.1124/jpet.110.167346.
  4. W.V. Bobo, Asenapine, Iloperidone and Lurasidone: Critical Appraisal of the Most Recently Approved Pharmacotherapies for Schizophrenia in Adults, Expert Rev. Clin. Pharmacol., 6, 61 (2013); https://doi.org/10.1586/ecp.12.70.
  5. R. Bawa and J.R. Scarff, Lurasidone: A New Treatment Option for Bipolar Depression-A Review, Innov. Clin. Neurosci., 12, 21 (2015).
  6. Latuda Prescribing Information, US FDA (2010).
  7. F. Kesisoglou, S. Panmai and Y. Wu, Nanosizing-Oral Formulation Development and Biopharmaceutical Evaluation, Adv. Drug Deliv. Rev., 59, 631 (2007); https://doi.org/10.1016/j.addr.2007.05.003.
  8. J.R. Madan, K.T. Pawar and K. Dua, Solubility Enhancement Studies on Lurasidone Hydrochloride using Mixed Hydrotropy, Int. J. Pharm. Investig., 5, 114 (2015); https://doi.org/10.4103/2230-973X.153390.
  9. M. Malamatari, K.M.G. Taylor, S. Malamataris, D. Douroumis and K. Kachrimanis, Pharmaceutical Nanocrystals: Production by Wet Milling and Applications, Drug Discov. Today, 23, 534 (2018); https://doi.org/10.1016/j.drudis.2018.01.016.
  10. F. Leone and R. Cavalli, Drug Nanosuspensions: A ZIP Tool Between Traditional and Innovative Pharmaceutical Formulations, Expert Opin. Drug Deliv., 12, 1607 (2015); https://doi.org/10.1517/17425247.2015.1043886.
  11. P.C. Kwok and H.K. Chan, Nanotechnology Versus other Techniques in Improving Drug Dissolution, Curr. Pharm. Des., 20, 474 (2014); https://doi.org/10.2174/13816128113199990400.
  12. R.H. Muller, R. Becker, B. Kross and K. Peters, Pharmaceutical Nanosus-pensions for Medicament Administration as Systems with Increased Saturation Solubility and Rate of Solution, US Patent 5858410 (1999).
  13. L. Bond, S. Allen, M.C. Davies, C.J. Roberts, A.P. Shivji, S.J.B. Tendler, P.M. Williams and J. Zhang, Differential Scanning Calorimetry and Scanning Thermal Microscopy Analysis of Pharmaceutical Materials, Int. J. Pharm., 243, 71 (2002); https://doi.org/10.1016/S0378-5173(02)00239-9.
  14. Á. Delgado, F. González-Caballero, R.J. Hunter, L.K. Koopal and J. Lyklema, J. Colloid Interface Sci., 309, 194 (2007); https://doi.org/10.1016/j.jcis.2006.12.075.
  15. S. Bose, D. Schenck, I. Ghosh, A. Hollywood, E. Maulit and C. Ruegger, Application of Spray Granulation for Conversion of a Nanosuspension into a Dry Powder Form, Eur. J. Pharm. Sci., 47, 35 (2012); https://doi.org/10.1016/j.ejps.2012.04.020.
  16. T. Venkatesh, A.K. Reddy, J.U. Maheswari, M.D. Dalith and C.K. Ashok Kumar, Nanosuspensions: Ideal Approach for the Drug Delivery of Poorly Water Soluble Drugs, Der Pharm. Lett., 3, 203 (2011).
  17. G.P. Kumar and K.G. Krishna, Nanosuspensions: The Solution to Deliver Hydrophobic Drugs, Int. J. Drug Deliv., 3, 546 (2011).
  18. P. Lakshmi and G.A. Kumar, Nano­Suspension Technology: A Review, Int. J. Pharm. Sci., 2, 35 (2010).
  19. R.H. Müller and G.E. Hildebrand, Zetapotential und Partikelladung in der Laborpraxis: Einfuhrung in die Theorie praktische Messdurchfuh-rung Dateninterpretation: Colloidal Drug Carriers, Paperback APV (1996).
  20. United States Food and Drug Administration Guidelines for Dissolution Testing of Lurasidone Hydrochloride; http://www.accessdata.fda.gov/scripts/cder/dissolution.
  21. E.M. Merisko-Liversidge and G.G. Liversidge, Drug Nanoparticles: Formulating Poorly Water-Soluble Compounds, Toxicol. Pathol., 36, 43 (2008); https://doi.org/10.1177/0192623307310946.